Literature DB >> 18600326

[Plasmacytoid carcinoma. Five case reports of a rare variant of urothelial carcinoma].

B Keck1, R Stöhr, P J Goebell, H M Fritsche, B Wullich, A Hartmann.   

Abstract

Plasmacytoid carcinoma is a rare variant of urothelial carcinoma and is characterised by distinct histopathological and clinical characteristics. The incidence varies between 2.7% and 3.1% of all muscle-invasive urothelial carcinoma. It is an aggressive, high-grade tumor with poor prognosis. Negative E-cadherin expression seems to be important for exact diagnosis. Systemic chemotherapy of plasmacytoid carcinoma could lead to prolonged patient survival.

Entities:  

Mesh：

Year:  2008        PMID： 18600326     DOI： 10.1007/s00292-008-1017-z

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  9 in total

1.  Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases.

Authors:  L R Zukerberg; N L Harris; R H Young
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

2.  Urothelial neoplasia with plasmacytoid morphology.

Authors:  J D Coyne; E Sim
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

3.  Plasmacytoid urothelial carcinoma of the bladder.

Authors:  Takurou Kohno; Masaya Kitamura; Hideyuki Akai; Minato Takaha; Kunimitsu Kawahara; Toshitugu Oka
Journal:  Int J Urol       Date:  2006-04       Impact factor: 3.369

Review 4.  Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications.

Authors:  Antonio Lopez-Beltran; Liang Cheng
Journal:  Hum Pathol       Date:  2006-07-31       Impact factor: 3.466

5.  Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases.

Authors:  Kien T Mai; Paul C Park; Hossein M Yazdi; Eric Saltel; Seyda Erdogan; William A Stinson; Ilias Cagiannos; Christopher Morash
Journal:  Eur Urol       Date:  2006-01-18       Impact factor: 20.096

6.  Plasmacytoid transitional cell carcinoma of the urinary bladder.

Authors:  Iraklis C Mitsogiannis; Maria G Ioannou; Chrissanthi D Sinani; Michael D Melekos
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

7.  Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.

Authors:  P M Cury; D N Butcher; C Fisher; B Corrin; A G Nicholson
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

8.  Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9.

Authors:  Keiji Shimada; Mitsutoshi Nakamura; Eiwa Ishida; Noboru Konishi
Journal:  Urology       Date:  2006-10       Impact factor: 2.649

9.  E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study.

Authors:  Tommaso Cai; Mauro Piazzini; Gabriella Nesi; Ilaria Taddei; Iacopo Sardi; Beatrice Detti; Nicola Mondaini; Maurizio Dal Canto; Riccardo Bartoletti
Journal:  Oncol Rep       Date:  2007-04       Impact factor: 3.906
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.